Biofrontera Q1 2024 GAAP EPS $(2.88) Misses $(1.17) Estimate, Sales $7.912M Miss $10.857M Estimate
Biofrontera Q1 2024 GAAP EPS $(2.88) Misses $(1.17) Estimate, Sales $7.912M Miss $10.857M Estimate
Biofrontera 2024 年第一季度公認會計准則每股收益 (2.88 美元) 未達到預期 (1.17) 美元，銷售額爲 791.2 萬美元，低於預期 1,085.7 萬美元
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(2.88) per share which missed the analyst consensus estimate of $(1.17) by 146.15 percent. This is a 48.57 percent increase over losses of $(5.60) per share from the same period last year. The company reported quarterly sales of $7.912 million which missed the analyst consensus estimate of $10.857 million by 27.12 percent. This is a 9.40 percent decrease over sales of $8.733 million the same period last year.
Biofrontera（納斯達克股票代碼：BFRI）公佈的季度虧損爲每股2.88美元，比分析師普遍預期的1.17美元（1.17美元）低146.15％。這比去年同期每股虧損5.60美元（5.60美元）增長了48.57％。該公司公佈的季度銷售額爲791.2萬美元，比分析師普遍預期的1,085.7萬美元低27.12％。這比去年同期的873.3萬美元的銷售額下降了9.40％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。